Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19436449 | 1.00 | PRSS1 (0.40) | PRSS1LMNASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL30234044 | 0.94 | LMNA (0.39) | PRSS1LMNASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL23077303 | 0.94 | LMNA (0.39) | PRSS1LMNASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL28751945 | 0.88 | PRSS1 (0.40) | PRSS1LMNASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL29686597 | 0.88 | PRSS1 (0.40) | PRSS1LMNASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL19451492 | 0.86 | PRSS1 (0.51) | PRSS1LMNASMN1; SMN2POLBMAPT | |
| SCHEMBL28752006 | 0.86 | PRSS1 (0.46) | PRSS1LMNASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL29686658 | 0.86 | PRSS1 (0.46) | PRSS1LMNASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL31454648 | 0.85 | PRSS1 (0.40) | PRSS1LMNASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL31016365 | 0.83 | PRSS1 (0.41) | PRSS1LMNASMN1; SMN2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4007758-B1 | BIS-[N-((5-CARBAMOYL)-1H-BENZO[D]IMIDAZOL-2-YL)-PYRAZOL-5-CARBOXAMIDE] DERIVATIVES AND RELATED COMPOUNDS AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS FOR THE TREATMENT OF CANCER | MERSANA THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | disclosed |
| CN-114981273-B | Heterocyclic amide compound, pharmaceutically acceptable salt thereof, preparation method and application thereof | 中国科学院上海药物研究所 | 2024-03-01 | — | — | CN | disclosed |
| CN-112351778-B | Fused tricyclic heterocycles and therapeutic uses thereof | 江苏恒瑞医药股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-11596692-B1 | PD-L1/STING conjugates and methods of use | INCYTE CORPORATION (US) | 2023-03-07 | — | — | US | disclosed |
| WO-2022246597-A1 | IMIDAZOPYRIDINE DERIVATIVES AS STING AGONISTS | FOREVER MILLETS LIMITED (CN) | 2022-12-01 | — | — | WO | disclosed |
| CN-112521371-B | Heterocyclic amide compound, pharmaceutically acceptable salt thereof, preparation method and application thereof | 中国药科大学 | 2022-11-25 | — | — | CN | disclosed |
| CN-113563313-B | Immunomodulator | 成都先导药物开发股份有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-114981273-A | Heterocyclic amide compound, pharmaceutically acceptable salt thereof, and preparation method and application thereof | 中国科学院上海药物研究所 | 2022-08-30 | — | — | CN | disclosed |
| EP-4007758-A1 | BIS-[N-((5-CARBAMOYL)-1H-BENZO[D]IMIDAZOL-2-YL)-PYRAZOL-5-CARBOXAMIDE] DERIVATIVES AND RELATED COMPOUNDS AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS FOR THE TREATMENT OF CANCER | Mersana Therapeutics, Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| CN-114585623-A | Bis [ N- ((5-carbamoyl) -1H-benzo [ d ] imidazol-2-yl) pyrazole-5-carboxamide ] derivatives and related compounds as STING (interferon gene stimulator) agonists for the treatment of cancer | 梅尔莎纳医疗公司 | 2022-06-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11596692-B1 | PD-L1/STING conjugates and methods of use | STING1, PDCD1LG2, CD274 | PRSS1 3956/4885LMNA 2058/4885SMN1; SMN2 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.